CANCER THERAPY: PRECLINICAL

NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

Beatriz Sánchez-Sánchez1,2, Sara Gutiérrez-Herrero2,3, Guillermo López-Ruano1,2, Rodrigo Prieto-Bermejo1,2, Marta Romo-González1,2, Marcial Llanillo1,2, Atanasio Pandiella2,3, Carmen Guerrero2,3, Jesús F. San Miguel2,4, Fermin Sánchez-Guijo2,4, Consuelo del Cañizo2,4, and Angel Hernández-Hernández1,2

Abstract

Purpose: Cancer cells show higher levels of reactive oxygen species (ROS) than normal cells and increasing intracellular ROS levels are becoming a recognized strategy against tumor cells. Thus, diminishing ROS levels could be also detrimental to cancer cells. We surmise that avoiding ROS generation would be a better option than quenching ROS with antioxidants. Chronic myelogenous leukemia (CML) is triggered by the expression of BCR-ABL kinase, whose activity leads to increased ROS production, partly through NADPH oxidases. Here, we assessed NADPH oxidases as therapeutic targets in CML.

Experimental Design: We have analyzed the effect of different NADPH oxidase inhibitors, either alone or in combination with BCR-ABL inhibitors, in CML cells and in two different animal models for CML.

Results: NADPH oxidase inhibition dramatically impaired the proliferation and viability of BCR-ABL expressing cells due to the attenuation of BCR-ABL signaling and a pronounced cell-cycle arrest. Moreover, the combination of NADPH oxidase inhibitors with BCR-ABL inhibitors was highly synergistic. Two different animal models underscore the effectiveness of NADPH oxidase inhibitors and their combination with BCR-ABL inhibitors for CML targeting in vivo.

Conclusion: Our results offer further therapeutic opportunities for CML, by targeting NADPH oxidases. In the future, it would be worthwhile conducting further experiments to ascertain the feasibility of translating such therapies to clinical practice. Clin Cancer Res; 1–12. ©2014 AACR.

Introduction

Chronic myelogenous leukemia (CML) is characterized by the t(9; 22) q(34; q11) translocation encoding the BCR-ABL oncoprotein, which triggers the chronic phase of the disease (1). BCR-ABL inhibitors are indicated for the frontline treatment of CML and lead to excellent therapeutic results (2). However, primary or secondary resistances to these treatments often result from the emergence of mutant forms of BCR-ABL, increasing a risk of progression to blast crisis (3, 4).

Excessive production of reactive oxygen species (ROS) has traditionally been associated with aging and degenerative diseases (5), but it is now becoming accepted that a moderate degree of ROS production, the so-called "redox signaling," is physiologically important (6). Cancer cells have higher levels of ROS than healthy cells (7, 8), suggesting that ROS could be important for the initiation and progression of cancer (9, 10), including leukemia (11). BCR-ABL–expressing cells also show high levels of ROS, which may contribute to cell transformation (12), cell growth (13), resistance to apoptosis (14), or increased DNA damage (15–17). The excess of ROS in BCR-ABL–expressing cells could come from mitochondria (12), enhanced glucose uptake (18), or the activity of NADPH oxidases (14). With the exception of mitochondria, NADPH oxidases are the main source of cellular ROS (19). This family consists of seven members (NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2). Each NADPH oxidase seems to have a particular pattern of expression, and most cells express different members of this family (20). The importance of these enzymes in cancer is beginning to be recognized (21) and, interestingly, it has recently been shown that NADPH oxidase inhibitors are efficient at preventing the growth of colon cancer xenografts (22). This suggests that NADPH oxidases could be exploited as therapeutic targets in the cancer treatment setting.

With the foregoing in mind, we were interested in evaluating the potential of NADPH oxidases as therapeutic targets in CML, either alone or in combination with NADPH oxidase inhibition.
BCR-ABL inhibitors. We show that the inhibition of NADPH oxidases dramatically impairs the proliferation and viability of BCR-ABL–expressing cells. Moreover, we observed a strong synergistic effect when NADPH oxidases and BCR-ABL inhibitors were combined. Two different animal models were studied and were seen to reflect the effectiveness of NADPH oxidase inhibitors and their combination with BCR-ABL inhibitors for CML targeting in vivo. Similar results were found in acute myelogenous leukemia (AML), and hence we suggest that this strategy could also be applied to other kinase-driven cancers such as acute myelogenous leukemia.

**Materials and Methods**

**Cell cultures**

Bone marrow mononuclear cells (BM-MNC) and CD34+ cells were isolated from patients and healthy donors as described (23). CD34+ and CD15+ cells were purified with a FACS Aria III cell sorter. Cell purity was above 93% (Supplementary Fig. S6B). K562, a human cell line derived from a patient with CML, was obtained from the ATCC (CCL 243). Boff 210 cells express p210 BCR-ABL constitutively and patient bone marrow cells was analyzed by culturing in HSC-CFU methylcellulose medium. One thousand K562 cells or 5,000 patient BM-MNCs were seeded per well in 0.5 mL of medium. Cells were grown at 37°C and 5% CO2 in an incubator and colonies were counted 14 days later.

**Analysis of drug interactions**

Drug interactions were analyzed according to the Chou-Talalay median-effect method (26), using CalcuSyn Software (Biosoft). The combination index (CI) < 1, CI = 1, or CI > 1 represents synergistic, additive, or antagonistic effects, respectively.

**Intracellular ROS levels**

ROS were measured using 2',7'-dichlorofluorescein diacetate as before (25).

**Immunoblotting**

Proteins cell extracts and immunoblotting were performed as reported previously (25). Quantification of bands was performed by densitometry with a CS-9000 Shimadzu equipment. Cell viability was determined by staining with annexin V-PE/7-AAD, as described previously (25).

**Animals**

Female CB17-SCID mice were purchased from Charles River Laboratory. Transgenic mice expressing p210 BCR-ABL in hematopoietic stem cells (HSC; *BCR-ABL*505) (27) were obtained from the RIKEN Bioresource Center. Animals were kept in specific pathogen-free animal facilities and monitored daily. The K562 cell xenograft tumor model in CB17-SCID mice was established by subcutaneous injection of 10^6 cells in 100 μL of RPMI-1640 medium and 100 μL of Matrigel. When the tumors became palpable, the mice were randomized to the control group (receiving the vehicle alone) or the different treatment groups and administered for 22 days with either, 1 mg/kg diphenyleneiodonium (DPI) (i.p.), 100 mg/kg imatinib (orally), or combinations of these drugs. The same treatment was applied over 2 weeks for young male or female *BCR-ABL*505 transgenic mice with high levels of neutrophils (50%). The effectiveness of the treatment was followed by analyzing the percentage of granulocytes (Gr1+) in peripheral blood. Animal experiments were approved by the Bioethics Committee of the University of Salamanca (Salamanca, Spain) according to EU and national laws.

**qRT-PCR and RNAi**

NADPH oxidases expression levels were analyzed by qRT-qPCR. Oligonucleotide sequences and technique details are available in Supplementary Tables.
are available in Supplementary Information. NOX2, NOX5, and DUOX2 expression was downregulated in K562 cells with specific shRNA (sequences available in Supplementary Information) by lentiviral infection as described (25). An oligonucleotide against firefly luciferase was used as a control (28).

Statistical analysis

Data are shown as mean ± SEM. Student t test or the Mann–Whitney U test, in the case of the animal models, were used to analyze statistical significance: ### P < 0.001, ## P < 0.01, # P < 0.05 when compared with control cells; *** P < 0.001, ** P < 0.01, * P < 0.05 when compared with kinase inhibitor-treated cells, and +++ P < 0.001, ++ P < 0.01, + P < 0.05 when compared with NADPH oxidase inhibitor-treated cells.

Results

The combination of NADPH oxidases inhibitors and BCR-ABL inhibitors hampers the proliferation of CML cells in a synergistic manner

Bearing in mind that NADPH oxidases contribute to BCR-ABL-mediated ROS production (14), we were prompted to evaluate these enzymes as molecular targets for CML treatment. DPI and apocynin, two different NADPH oxidases inhibitors, hampered the proliferation of two different CML cell lines in a dose-dependent manner (Fig. 1 and Supplementary Fig. S1). Moreover, the combination of the BCR-ABL inhibitor imatinib with DPI was significantly more effective than either individual treatment (Fig. 1A, B, and D).

Analysis of these combinations by the Chou-Talalay method (26) revealed a CI lower than 1, reflecting high synergism (Fig. 1C and E). The same synergy was found when different inhibitors for BCR-ABL (nilotinib) or NADPH oxidases (apocynin) were used (Supplementary Fig. S1C and S1D). Although DPI and apocynin are commonly used to target NADPH oxidases, they are not specific. DPI is a uncompetitive inhibitor of flavoproteins and therefore at high concentrations targets other flavoproteins. Apocynin prevents the assembly of NOX2 complex, although it may exert other effects (29). Accordingly, we tested a novel inhibitor, VAS3947, that is apparently specific toward NADPH oxidases (30). The combination of VAS3947 with imatinib was also synergistic (Supplementary Fig. S1E), suggesting that the effects observed when using DPI or apocynin were indeed due to the inhibition of NADPH oxidases.

When we applied the same strategy to BM-MNC isolated from newly diagnosed patients with CML who had not yet started treatment, the results were very similar to those described for CML cell lines, the combined treatment proved to be significantly more effective than the individual treatments (Fig. 2A, B, and E). Moreover, the CI was lower than 1 (Fig. 2C and D), especially with the nilotinib combinations, also indicating a synergistic effect. Interestingly, we did not observe synergy when BM-MNCs from healthy donors were used. (Supplementary Fig. S2).

Furthermore, we analyzed the response of hematopoietic progenitors to these treatments. After 24 hours of incubation, the number of CD34+ cells isolated from patients with CML was significantly reduced by DPI or the combined treatment. Interestingly, CD34+ cells isolated from healthy donors were unaffected by the same treatments (Fig. 2F).

Inhibition of NADPH oxidases is effective for the in vivo treatment of CML

To evaluate the possible use of NADPH oxidase inhibitors for in vivo CML treatment, we initially used a K562 cell xenograft model in CB17-SCID mice. As expected, imatinib treatment slowed tumor growth significantly (Fig. 3A). Moreover, DPI treatment showed a similar effect to that described for imatinib (Fig. 3A), suggesting that in vivo treatment with NADPH oxidase inhibitors could be a good strategy for CML treatment. Furthermore, the combined treatment showed a clear trend toward greater effectiveness than the single treatments, in agreement with the synergy observed in vitro.

We also used a transgenic mouse line, in which BCR-ABL is specifically expressed in HSCs (27), that elicits a myeloproliferative syndrome very similar to human CML (1). Individual imatinib or DPI treatments reduced the number of granulocytes in peripheral blood, whereas their combination was significantly more effective (Fig. 3C).

We did not find significant differences in the animals' weights between the different experimental groups (Fig. 3B and D), suggesting that the treatments were well tolerated. Thus, in keeping with our in vitro observations, two different in vivo animal models show that NADPH oxidase inhibitors are effective for CML treatment, and that these inhibitors can enhance the activity of standard BCR-ABL inhibitors.

NADPH oxidase and BCR-ABL inhibitors reduce intracellular ROS levels

Bearing in mind the strong synergism observed when NADPH oxidase and BCR-ABL inhibitors were combined, we sought to understand the mechanism of these effects. Individual treatments led to a slight reduction in the content of intracellular ROS levels, whereas combination therapy caused a further decrease in such levels, both in K562 cells (Fig. 4A) and in BM-MNC from patients (Fig. 4B). This decrease could be related to the mechanism of action of these drugs. Indeed, two different antioxidants, N-acetyl cysteine and quercetin, inhibited K562 cell proliferation (Supplementary Fig. S3A and S3B). Moreover, rotenone, an inhibitor of mitochondrial complex I, hampered cell proliferation (Supplementary Fig. S3C) and reduced the intracellular ROS content (Supplementary Fig. S3D). These results suggest that CML cell proliferation would be correlated with the levels of intracellular ROS, and support the notion that decreasing the ROS content could be a good strategy for inhibiting CML cell proliferation.
Figure 1. Inhibitors of NADPH oxidases and BCR-ABL synergize to avoid the proliferation of CML cell lines. K562 and Boff 210 cells were treated with DPI, imatinib, or a combination thereof for 48 and 24 hours, respectively. A, K562 cell proliferation. B, K562 cell colony-forming assays. C, drug interaction in K562 cells. A representative experiment is shown, and the CIs (mean ± SE) of eight different experiments are depicted. D, Boff 210 cell proliferation. E, drug interaction in Boff 210 cells. A representative experiment is shown, and the CIs (mean ± SE) of four different experiments are depicted.
Figure 2. Inhibitors of NADPH oxidases and BCR-ABL synergize to prevent the proliferation of BM-MNC from patients with CML. Proliferation of BM-MNC treated 48 hours with imatinib, DPI, or their combination (A), or with nilotinib, DPI, or their combination (B). Analysis of the interaction of DPI with imatinib (C) or with nilotinib (D). A representative experiment and the CIs of different patients are shown. E, colony-forming assays upon treatment with imatinib, DPI, or their combination. F, CD34⁺ cells isolated from patients with CML or from healthy donors were treated with imatinib, DPI, or a combination thereof. The number of cells was counted 24 hours later and normalized to untreated control cells.

Published OnlineFirst May 15, 2014; DOI: 10.1158/1078-0432.CCR-13-3044
NADPH oxidase activity contributes to maintaining the activation of the BCR-ABL signaling

Because ROS can regulate cellular signaling (6) and the cell cycle (31), we analyzed both aspects. As expected, imatinib produced a strong inhibition of BCR-ABL phosphorylation in K562 cells (Fig. 4C). Interestingly, DPI alone also produced a noticeable decrease in BCR-ABL phosphorylation and, more importantly, the combination induced a further decrease in BCR-ABL activation (Fig. 4C), explaining, at least in part, the strong inhibition of cell proliferation and the clonogenic capacity reported above.

Interestingly, DPI treatment reduced BCR-ABL protein levels, without affecting the mRNA (Fig. 4C and Supplementary Fig. S3E–S3G), suggesting that NADPH oxidases would regulate BCR-ABL protein stability.

We also looked at downstream effectors of BCR-ABL. The activation status of CRKL and STAT5 was also affected by single treatments and, in agreement with what we observed for BCR-ABL phosphorylation, the combined treatment produced a significantly stronger inhibition (Fig. 4D). In the case of ERK1/2, the combination of imatinib plus DPI did not seem to produce a stronger inhibition than imatinib alone (Fig. 4D). However, when we combined nilotinib and DPI, ERK1/2 phosphorylation was significantly reduced in comparison with single treatments (Fig. 4E).

These results suggest that NADPH oxidase-driven ROS production is necessary to maintain the activation of the BCR-ABL signaling pathway, perhaps through the inactivation of protein tyrosine phosphatases (PTP), given the...
NADPH Oxidase Inhibitors and BCR-ABL Inhibitors Synergize

Figure 4. NADPH oxidase-driven ROS production contributes to maintaining the activation of the BCR-ABL signaling pathway. Intracellular ROS levels upon 2 hours treatment with imatinib, DPI, or their combination, in K562 cells (A) or BM-MNC isolated from three different patients with CML (B). K562 cells treated with imatinib or nilotinib, DPI, or their combinations for 16 hours were used to analyze the activation of BCR-ABL (C), or some of its downstream targets (D and E).

sensitivity of these enzymes to oxidation (6). In this regard, it is interesting to note that a role for SHP1 as a BCR-ABL tumor suppressor was proposed some time ago (32). SHP1-specific activity was enhanced by imatinib, DPI, or their combination (Supplementary Fig. S4A), suggesting that the increase in SHP1 activity, due to a lower level of oxidative stress, could be related to BCR-ABL signaling attenuation. This effect seems to be specific to SHP1 because the activity of the closely related SHP2 was not affected by DPI treatment (Supplementary Fig. S4B), and moreover, the inhibition of SHP2 did not alter cell proliferation (Supplementary Fig. S4C).

It has recently been reported that DPI inhibits the expression of multidrug resistance-1 gene (MDR1) in hepatocellular carcinoma cells (33), which can alter drug pharmacodynamics. However, DPI did not altered MDR1 messenger levels in K562 cells (Supplementary Fig. S4D). Because Rac GTPase seems to be a suitable therapeutic target for CML (34), and because some NADPH oxidase complexes depend on Rac, we analyzed the GTPase activity upon DPI treatment, but found no differences with the control (Supplementary Fig. S4E).

**NADPH oxidase inhibition blocks cell-cycle progression and affects cell viability**

Cell-cycle analysis showed that DPI induced a pronounced G2-M phase arrest (Fig. 5A and B). The increase in phospho-histone H3 (S10; ref. 35) and the decrease in WEE1 (ref. 36; Fig. 5C) are consistent with an arrest in mitosis. An increase in the dsDNA break marker, γH2AX, was also observed (Fig. 5D). There was a substantial increase in cell numbers in the sub-G1 phase (Fig. 5A and Supplementary Fig. S5A), especially with the combined treatment. This suggests that the cells cannot overcome this cell-cycle arrest, and therefore that they are destined for apoptosis, which could also explain the synergistic effect of the combined treatments. Indeed, all treatments increased cell death, but the combination showed a tendency toward a
higher percentage of early apoptotic cells (Annexin V⁺/7AAD⁻ cells; Fig. 5E), in agreement with the higher number of cells in the sub-G₁ phase after the combined treatment.

CML cells express different NADPH oxidase isoforms

Most cells express several NADPH oxidases (37) and hence an intriguing issue is whether there is functional specificity between them or whether, instead, there is redundancy. It
Figure 6. CML and myeloid cells express several NADPH oxidases. NADPH oxidase downregulation in K562 cells decreases proliferation and clonogenic capacity and hampers BCR-ABL signaling. The pattern of expression of NADPH oxidases was analyzed by RT-qPCR. The reaction was repeated at least three times. A, relative expression of NADPH oxidases in K562 cells. B, NOX2, NOX5, or DUOX2 was downregulated by RNAi in K562 cells. Relative expression of each isoform in the corresponding downregulated cell line, considering expression in control cells as 1. (Continued on the following page.)
would be interesting to settle this issue for CML cells to evaluate the appropriateness of seeking novel pan-inhibitors or specific inhibitors against particular isozymes. Our analysis shows that K562 cells express NOX2, NOX5, and DUOX2 (Fig. 6A), NOX2 being the predominant isoform.

To test whether BCR-ABL signaling was affected by any particular NADPH oxidase, we generated stable cell lines whose expression was downregulated (Fig. 6B). The clonogenic capacity of all these cell lines was significantly reduced with respect to control cells (Fig. 6C). Moreover, BCR-ABL signaling was also attenuated when any of the NADPH oxidases was downregulated, since we detected a decrease in the activation and levels of BCR-ABL (Fig. 6D), and in the activation status of, ERK1/2 and STAT5 (Fig. 6E). These results are in agreement with a redundancy of function of the three NADPH oxidases expressed in K562 cells, at least about BCR-ABL signaling and clonogenic capacity. We generated stable cell lines in which pairwise combinations or the three Nox were downregulated at the same time (Supplementary Fig. S7A). The activation of BCR-ABL signaling was more compromised in these cell lines than in the individual knockdowns (Supplementary Fig. S7B and S7C). These results suggest that BCR-ABL would not rely on a unique NOX isoform to maintain its signaling activated. This also means that it would be more effective to target all Nox isoforms rather than a particular one to hamper BCR-ABL signaling.

We next analyzed the pattern of expression in BM-MNC from 4 different patients (Fig. 6F). NOX2 and NOX5 were present in all the patients analyzed. DUOX1 or DUOX2 were expressed in 3 out of 4 patients, and only one of the patients expressed NOX3.

We also analyzed the NADPH oxidase pattern of expression at different stages of myeloid differentiation in healthy donors. Interestingly, immature CD34+ progenitors expressed all NADPH oxidases except NOX1 and NOX4 (Fig. 6G). This pattern of expression differs from that reported by Piccoli and colleagues (38). In their study, the authors used CD34+ cells isolated from peripheral blood after mobilization with G-CSF, but failed to perform an analysis of the relative expression of the different Nox isoforms, whereas we purified CD34+ cells from BM-MNC. CD33+ myeloid progenitors expressed mainly NOX2 and NOX5, whereas mature CD15+ myeloid cells expressed NOX2, NOX5, DUOX1, and DUOX2 (Fig. 6G), an expression profile very similar to that of CML patients BM-MNC (Fig. 6F). It is worth mentioning that NOX2 was always the most abundant isoform, and that NOX5 was present in all the types of hematopoietic cells analyzed.

**NADPH oxidases as therapeutic targets in acute myeloid leukemia**

Our results support the notion that NADPH oxidases are necessary to maintain the activation of BCR-ABL signaling, which would explain the synergistic effect of the combined treatment. Other oncogenic kinases seem to increase the production of ROS through NADPH oxidases (39). Therefore, we speculated that the same strategy as that followed here could be applied to other kinase-driven cancers. We attempted to check this in AML cells expressing the activating mutation of FMS-like tyrosine kinase-3 (FLT3-ITD), because it has been reported that NADPH oxidase ROS production promotes AML cells proliferation (40), and moreover FLT3-ITD activates ROS production through NADPH oxidases (11). We tested two different FLT3-ITD inhibitors (midostaurin and sorafenib) combined with DPI in two FLT3-ITD–expressing cell lines (MOLM-13 and MV411). As occurred for CML cells, DPI also inhibited the proliferation of both the AML cell lines, and the combined treatments proved to be synergistic (Fig. 6H and Supplementary Fig. S8). Therefore, our results show that combining kinase inhibitors with NADPH oxidase inhibitors would offer a therapeutic strategy to be considered in kinase-driven cancers.

**Discussion**

Cancer cells have higher levels of intracellular ROS than healthy cells (7, 8), which may somehow contribute to cell transformation (9, 10). The idea of exploiting this difference in the therapeutic arena was proposed a few years ago (41), and interest has now been rekindled (6, 42). ROS-enhancing treatments would induce cancer cells to cross an oxidative stress threshold incompatible with cell viability, whereas healthy cells would be spared, because they would not reach that lethal threshold. The number of contributions describing treatments based on this strategy is expanding rapidly, including a recent report showing the feasibility of using this strategy in BCR-ABL–positive cells too (14).

Given that elevated intracellular levels of ROS seem to contribute to cancer cell proliferation and survival, we reasoned that reducing ROS levels might be also a good strategy to combat cancer cells. In fact, antioxidant intake to prevent stress-related process such as ageing or cancer is an old and very popular idea (43). However, if we knew the source of ROS in cancer cells, we could prevent their occurrence, which strikes us as being a better strategy than the simple use of ROS scavengers to reduce oxidative stress indiscriminately. Accordingly, we analyzed the possible use of NADPH oxidases as therapeutic targets in CML. The reason for this choice is that it has long been known that BCR-ABL triggers ROS production (12). More recently, it has been suggested that NADPH oxidases contribute to

(Continued.) C, colony assays in Nox downregulated cell lines. D, BCR-ABL protein and phosphorylation levels in Nox downregulated cell lines. E, ERK1/2 and STAT5 activation in Nox downregulated cell lines. F, relative expression of NADPH oxidases in BM-MNC from patients with CML. G, relative expression of NADPH oxidases in CD34+, CD33+, and CD15+ cells from healthy donors. H, proliferation of MV4-11 cells treated with DPI, FLT3-ITD inhibitors (midostaurin and sorafenib), or combinations thereof for 48 hours. Interaction between DPI and midostaurin or DPI and Sorafenib. A representative experiment for each combination, and the CIs (mean ± SE) of three or five different experiments for sorafenib and midostaurin, respectively, are depicted.
BCR-ABL-driven ROS production (14), and ROS seem to be important for the regulation of the growth of BCR-ABL-expressing cells (18). However, the possible use of this family of enzymes as therapeutic targets in CML has not yet been addressed.

NADPH oxidase inhibitors effectively hamper the proliferation and clonogenic capacity of CML cells, also inducing a pronounced cell-cycle arrest in mitosis. NADPH oxidase inhibitors were also seen to be effective in vivo in two different animal models, supporting the possible future use of this strategy in the treatment of CML. Moreover, the combinatorial use of BCR-ABL and NADPH oxidase inhibitors proved to be highly synergistic, opening the possibility of using this strategy in the future for the improvement of CML treatment.

Intracellular ROS levels were significantly reduced upon treatment with NADPH oxidases and BCR-ABL inhibitors. Antioxidants or rotenone treatment also impaired CML cell proliferation. And hence we propose that the capacity of NADPH oxidase and BCR-ABL inhibitors to hamper CML cell proliferation would be linked to their ability to reduce intracellular ROS levels.

NADPH oxidases inhibitors prevented the full activation of BCR-ABL signaling. Accordingly, BCR-ABL activation of NADPH oxidase-driven ROS production would represent a feed-forward mechanism aimed at sustaining the activation of the signaling pathway. A feasible way of attaining this would be through the oxidation and inhibition of PTPs, such as SHP1.

Downregulating the different Nox isoforms expressed in K562 cells caused effects similar to those elicited by the use of chemical inhibitors. We did not find any specificity among the different NADPH oxidases, therefore, the strategy for the future would be to search for novel NADPH oxidase pan-inhibitors rather than looking for molecules specific toward a particular NADPH oxidase.

Finally, we show that inhibition of NADPH oxidases hampered the proliferation of AML cells, and the combination of NADPH oxidase inhibitors with FLT3-ITD inhibitors was also synergistic. NADPH oxidases may be important for sustaining the signaling activated by oncogenic kinases. Therefore, we propose that NADPH oxidases could be interesting therapeutic targets not only for CML or AML but also for any other kinase-driven cancer.

In sum, our results demonstrate that targeting NADPH oxidases could be an appropriate strategy for CML treatment because of the effectiveness of their inhibition in vitro and in vivo, and also because of the high degree of synergism observed when they are combined with BCR-ABL inhibitors. This could improve traditional therapy for this disease and could be a good strategy for either preventing the appearance of resistances to BCR-ABL inhibitors, or for consideration as an alternative in the event of such resistances already existing.

Disclosure of Potential Conflicts of Interest

J. F. San Miguel is a consultant/advisory board member for Bristol-Myers Squibb, Celgene, Janssen, Merck Sharp & Dohme, Millennium, Novartis, and Onyx. M.-C. del Cañizo reports receiving other commercial research support from Celgene, Jansen-Cilag, and Novartis. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: J. F. San Miguel, A. Hernández-Hernández


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Pandiella, C. Guererro, F. Sánchez-Guijo, C. del Cañizo

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B. Sánchez-Sánchez, A. Pandiella, C. Guererro, A. Hernández-Hernández

Writing, review, and or revision of the manuscript: B. Sánchez-Sánchez, M. Llanillo, C. Guererro, J. F. San Miguel, F. Sánchez-Guijo, C. del Cañizo, A. Hernández-Hernández

Study supervision: C. Guererro, C. del Cañizo, A. Hernández-Hernández

Other (conducted animal experiment): S. Gutiérrez-Herrero

Acknowledgments

The authors thank Dr. D. Trono for providing lentiviral vectors, María Sacristán for her invaluable help with the cell-cycle experiments, and Dr. Honda for giving the permission to use the BCR-ABL(5/6) transgenic mice.

Grant Support

This work was supported by BFU2006-10362, BFU2009-10568, CSD2007-00015, BFU2011-28467, SA10A10-2, SA126A07, BIO/SAS9/13 and ES/S7/2012. G.L.P. had a predoctoral fellowship from the Regional Government of Castilla y León, Spain.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 5, 2013; revised May 5, 2014; accepted May 6, 2014; published OnlineFirst May 15, 2014.

References


Clinical Cancer Research

NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia

Clin Cancer Res  Published OnlineFirst May 15, 2014.

Updated version  Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-3044

Supplementary Material  Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/05/14/1078-0432.CCR-13-3044.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/early/2014/07/07/1078-0432.CCR-13-3044. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.